rawfin.tv
Biostem Raises 2026 Revenue Outlook, Targets H1 2027 Manufacturing Transfer
MarketsstocksAI Generated

Biostem Raises 2026 Revenue Outlook, Targets H1 2027 Manufacturing Transfer

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Biostem Corp. increased its 2026 revenue outlook to a range of $26 million to $29 million. The company also announced plans to complete a manufacturing transfer in the first half of 2027.

BiotechnologyRevenue GuidanceManufacturing

Related Articles

China Equities Lag US Stocks by Record 2.095 Valuation Ratio

China Equities Lag US Stocks by Record 2.095 Valuation Ratio

stocks
S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

stocks
Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

stocks
Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

stocks